The peripheral and central mechanisms of transition of acute to chronic pain and the possible role of cyclooxygenase-2 inhibition in the prevention of pain syndrome chronization
https://doi.org/10.14412/2074-2711-2016-2-10-16
Abstract
Chronic pain syndromes as a cause of suffering, short-term or persistent disability, and social losses greatly worsen quality of life. The mechanisms leading to the occurrence and maintenance of chronic pain are traditionally of interest for in-depth study since each of them is potentially a target for pharmacotherapy. Peripheral and central sensitizations, as well as disinhibition make different contributions to the development of chronic pain. The fact that cyclooxygenase-2 (COX-2) inhibitors may affect at both the peripheral and central, spinal levels, by modulating such a phenomenon as central sensitization, has been recently discussed. There are theoretical prerequisites for a discussion of this action of COX-2 inhibitors; however, clinical findings supporting this hypothesis have been scarce so far. In this connection, of interest is the clinical trial published in 2016, which may suggest to a high degree of accuracy that some analgesic effect of the selective COX-2 inhibitor etoricoxib is realized through the central mechanisms of pain modulation.
About the Author
O. S. Davydov
Z.P. Solovyev Research and Practical Center of Psychoneurology, Moscow Healthcare Department, Moscow
Russian Federation
Russian Federation
43, Donskaya St., Moscow 115419
References
1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140- 6736(15)60692-4. Epub 2015 Jun 7.
2. Яхно НН, Кукушкин МЛ, Чурюканов МВ, Сыровегин АВ. Результаты открытого мультицентрового исследования «МЕРИДИАН» по оценке распространенности болевых синдромов в амбулаторной практике и терапевтических предпочтений врачей. Российский журнал боли. 2012;(3):10-4. [Yakhno NN, Kukushkin ML, Churyukanov MV, Syrovegin AV. The results of an open multicenter study «MERIDIAN» on the assessment of the prevalence of pain syndromes in the outpatient clinic and therapeutic preferences of doctors. Rossiiskii zhurnal boli. 2012;(3):10-4. (In Russ.)].
3. Jackson T, Thomas S, Stabile V, et al. Prevalence of chronic pain in low-income and middleincome countries: a systematic review and meta-analysis. Lancet. 2015 Apr 27;385 Suppl 2:S10. doi: 10.1016/S0140- 6736(15)60805-4. Epub 2015 Apr 26.
4. Gatchel RJ, McGeary DD, McGeary CA, Lippe B. Interdisciplinary Chronic Pain Management: Past, Present, and Future. Am Psychol. 2014 Feb-Mar;69(2):119-30. doi: 10.1037/a0035514.
5. Gatchel RJ, Peng YB, Peters ML, et al. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull. 2007 Jul;133(4):581-624.
6. Данилов АБ. Управление болью. Биопси- хосоциальный подход. Москва: АММ ПРЕСС; 2012. 292 с. [Danilov AB. Upravlenie bol'yu. Biopsikhosotsial'nyi podkhod [The management of pain. Biopsychosocial approach]. Moscow: AMM PRESS; 2012. 292 p.]
7. Toth C. Peripheral and Central sensitization. In: Toth C, Moulin DE, editors. Neuropathic Pain: Causes, Management, and Understanding. Cambridge University Press; 2013. P. 51-64.
8. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009 Sep;10(9):895-926. doi: 10.1016/j.jpain.2009.06.012.
9. Кукушкин МЛ, Подчуфарова ЕВ, Яхно НН. Физиология и патофизиология боли. В кн.: Яхно НН, Кукушкин МЛ, редакторы. Боль (практическое руководство для врачей). Москва: Издательство РАМН; 2011. С.12-30. [Kukushkin ML, Podchufarova EV, Yakhno NN. Physiology and pathophysiology of pain. In: Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for physicians)]. Moscow: Izdatel'stvo RAMN; 2011. P.12-30.]
10. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011 Mar;152(3 Suppl):S2-15. doi: 10.1016/j.pain.2010.09.030. Epub 2010 Oct 18.
11. Handwerker H. Peripheral and central sensitization as risk factors of low back pain. In: Hasenbring MI, Rusu AC, Turk DC, editors. From Acute to Chronic Back Pain: Risk Factors, Mechanisms and Clinical Implications. Oxford: Oxford University Press; 2012. P. 287-310.
12. Arendt-Nielsen L. Central sensitization in humans: assessment and pharmacology. Handb Exp Pharmacol. 2015;227:79-102. doi: 10.1007/978-3-662-46450-2_5.
13. Данилов АБ, Давыдов ОС. Биологические и патологические аспекты боли. В кн: Нейропатическая боль. Москва: Боргес; 2007. С. 56-69. [Danilov AB, Davydov OS Biological and pathological aspects of pain. In: Neiropaticheskaya bol' [Neuropathic pain]. Moscow: Borges; 2007. P. 56-69.]
14. Каратеев АЕ, Яхно НН, Лазебник ЛБ и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Москва: ИМА-ПРЕСС; 2009. 168 c. [Karateev AE, Yakhno NN, Lazebnik LB, et al. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii [The use of nonsteroidal antiinflammatory drugs. Clinical guidelines]. Moscow: IMA-PRESS; 2009. 168 p.]
15. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001 Mar 22; 410(6827):471-5.
16. Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases [correction of cycloxygenases] in the spinal cord. Prog Neurobiol. 2001 Jul;64(4):327-63.
17. Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992 Aug 28;257(5074):1276-9.
18. Yamamoto T, Sakashita Y. COX-2 inhibitor prevents the development of hyperalgesia induced by intrathecal NMDA or AMPA. Neuroreport. 1998 Dec1;9(17):3869-73.
19. Euchenhofer C, Maihоfner C, Brune K, et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett. 1998 May 22;248(1):25-8.
20. Telleria-Diaz A, Schmidt M, Kreusch S, et al. Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids. Pain. 2010 Jan;148(1):26-35.
21. Burns D, Hill L, Essandoh M, et al. Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: a randomized controlled trial in healthy volunteers. BMC Anesthesiol. 2006 Mar 10;6:3.
22. Willert RP, Delaney C, Hobson AR, et al. Constitutive cyclooxygenase-2 does not contribute to the development of human visceral pain hypersensitivity. Eur J Pain. 2006 Aug;10(6):487-94. Epub 2005 Aug 24.
23. Martin F, Fletcher D, Chauvin M, Bouhassira D. Constitutive cyclooxygenase-2 is involved in central nociceptive processes in humans. Anesthesiology. 2007 May;106(5):1013-8.
24. Sycha T, Anzenhofer S, Lehr S, et al. Rofecoxib attenuates both primary and secondary inflammatory hyperalgesia: a randomized, double blinded, placebo controlled crossover trial in the UV-B pain model. Pain. 2005 Feb;113(3):316-22.
25. Renner B, Zacher J, Buvanendran A, et al. Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery – a pilot study. Naunyn Schmiedebergs Arch Pharmacol. 2010 Feb;381(2):127-36.
26. Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology. 2005 Feb;102(2):409-15.
27. Arendt-Nielsen L, Egsgaard LL, Petersen KK. Evidence for a central mode of action for etoricoxib (COX-2 Inhibitor) in patients with painful knee osteoarthritis. Pain. 2016 Mar 22. [Epub ahead of print].
28. Croom KF, Siddiqui MA. Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis. Drugs. 2009 Jul 30;69(11):1513-32.
29. Lin HY, Cheng TT, Wang JH, et al. Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial. Int J Rheum Dis. 2010 May;13(2):144-50.
Review
For citations:
Davydov O.S. The peripheral and central mechanisms of transition of acute to chronic pain and the possible role of cyclooxygenase-2 inhibition in the prevention of pain syndrome chronization. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(2):10-16. (In Russ.) https://doi.org/10.14412/2074-2711-2016-2-10-16
Views: 1171
Email this article 